Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target
Authors:
- F. De VitaFVF. De Vita
- F. GiulianiFGF. Giuliani
- N. SilvestrisNSN. Silvestris
- G. CatalanoGCG. Catalano
- F. CiardielloFCF. Ciardiello
- M. OrdituraMOM. Orditura
- 1 November 2010
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 36, S11-S15
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- The role of HER2 in cancer therapy and targeted drug deliveryJournal of Controlled Release, 2010
- Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivoClinical Cancer Research, 2010
- The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell linesCancer Letters, 2008
- Assessment of a HER2 scoring system for gastric cancer: results from a validation studyHistopathology, 2008
- Neo-adjuvant and adjuvant chemotherapy of gastric cancerAnnals of Oncology, 2007
- Chemoradiotherapy as adjuvant treatment of gastric cancerAnnals of Oncology, 2007
- Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumabAnnals of Oncology, 2005
- The epidemiology of gastric cancerSeminars in Radiation Oncology, 2002
- Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancerBritish Journal of Cancer, 1995
- Clinicopathological significance of c‐erbB‐2 protein expression in human gastric carcinomaJournal of Surgical Oncology, 1992